Loading…
Sight Sciences, Inc. is projected to rise to $7.36 by 2027, a +38% move from its current price of $5.32. SGHT is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $5.18 | $5.32 | $5.47 | +0.03% |
| Jul 14 | $5.12 | $5.32 | $5.54 | +0.06% |
| Jul 15 | $5.07 | $5.32 | $5.59 | +0.09% |
| Jul 16 | $5.04 | $5.33 | $5.63 | +0.12% |
| Jul 17 | $5.01 | $5.33 | $5.67 | +0.15% |
| Jul 18 | $4.98 | $5.33 | $5.71 | +0.19% |
| Jul 19 | $4.95 | $5.33 | $5.74 | +0.22% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.95 | $5.33 | $5.74 | +0.22% |
| Week 2 | $4.81 | $5.34 | $5.93 | +0.43% |
| Week 3 | $4.71 | $5.35 | $6.09 | +0.65% |
| Week 4 | $4.63 | $5.37 | $6.22 | +0.87% |
| Week 5 | $4.56 | $5.38 | $6.34 | +1.09% |
| Week 6 | $4.50 | $5.39 | $6.46 | +1.31% |
| Week 7 | $4.44 | $5.40 | $6.57 | +1.53% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Sight Sciences, Inc. is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye.
It offers OMNI, a surgical system family of products, such as OMNI Ergo for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and OMNI EDGE, an implant-free and minimally invasive glaucoma surgery technology. The company also provides SION, a bladeless and manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork; and TearCare system, a proprietary, interventional, dry eye device designed to melt and facilitate the comprehensive removal of meibomian gland obstructions and restore gland functionality and healthy oil production for adult patients with evaporative dry eye disease when used in conjunction with manual expression of the meibomian glands for ophthalmologists and optometrists. It serves hospitals, medical centers, and eyecare professionals through sales representatives and distributors.
The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Sight Sciences, Inc. is currently trading with a price of $5.26 and sits in the Healthcare sector as a listed company. Its market position is reflected in a rank of 3563 and a market capitalization of $286.2M.
The stock shows a mixed but increasingly constructive longer-term backdrop with a forecast that projects higher average prices in coming years. For example, the year 2026 is forecast to have an average price of $5.26, with stronger upside expected in subsequent years, including a 2030 average of $9.05 and a 2040 average of $25.28, followed by a 2050 average of $45.21, accompanied by progressively larger ROI figures.
A major floor 35.2% below — a decisive break under it would weaken the trend.
The nearest floor, 18.4% below — buyers have tended to step in here.
The nearest ceiling, 9.8% above — a clean break opens room to run.
A major ceiling 25.3% above — clearing it would confirm fresh momentum.
Key SGHT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SGHT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $5.35 | Sell | $5.35 | Sell |
| MA 10 | $5.46 | Sell | $5.37 | Sell |
| MA 20 | $5.32 | Sell | $5.28 | Buy |
| MA 50 | $4.98 | Buy | $5.03 | Buy |
| MA 100 | $4.59 | Buy | $4.99 | Buy |
| MA 200 | $5.41 | Sell | $4.98 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 53.64 | Neutral |
| Stoch RSI (14) | 9.39 | Buy |
| CCI (20) | -1.09 | Neutral |
| Williams %R (14) | -86.67 | Info |
| MACD (12,26,9) | -0.04 | Sell |
| ROC (12) | -1.66 | Sell |
| Bollinger %B (20,2) | 0.50 | Neutral |
| Stochastic %K (14) | 13.33 | Buy |
| TRIX (15) | 0.53 | Buy |
| Awesome (5,34) | 0.26 | Buy |
| Ultimate (7,14,28) | 42.90 | Neutral |
| Momentum (10) | -0.14 | Sell |
| Aroon Osc (25) | 68.00 | Buy |
| Hull MA (9) | 5.26 | Buy |
| ADX (14) | 15.98 | Neutral |
| ATR (14) | 0.12 | Info |
The 30-day technical picture shows near-term momentum that is broadly neutral to slightly bullish. The RSI(14) is 50, suggesting neutral momentum. The stock price sits between the 50-day and 200-day moving averages, with SMA50 at $4.96 and SMA200 at $5.40.
Support is indicated at $4.34 and resistance at $5.84, while the 30-day price range spans $4.35 to $6.35.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.45 | $5.32 | $7.49 | 0% | Neutral | |
| $5.85 | $7.36 | $9.81 | +38% | Bullish | |
| $5.99 | $7.76 | $10.74 | +46% | Bullish | |
| $6.25 | $8.29 | $11.81 | +56% | Bullish | |
| $6.49 | $8.78 | $12.83 | +65% | Bullish | |
| $6.75 | $9.31 | $13.90 | +75% | Bullish | |
| $8.08 | $11.35 | $17.27 | +113% | Bullish | |
| $9.03 | $12.90 | $19.98 | +142% | Bullish | |
| $9.81 | $14.24 | $22.41 | +168% | Bullish | |
| $10.39 | $15.31 | $24.47 | +188% | Bullish | |
| $14.71 | $23.23 | $39.51 | +337% | Bullish | |
| $22.85 | $40.65 | $75.75 | +664% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $3.45 | $5.32 | $6.48 | +0.00% |
| August 2026 | $4.70 | $5.56 | $6.74 | +4.43% |
| September 2026 | $4.60 | $5.47 | $6.71 | -1.50% |
| October 2026 | $4.62 | $5.53 | $6.85 | +1.06% |
| November 2026 | $4.84 | $5.82 | $7.27 | +5.32% |
| December 2026 | $4.93 | $5.96 | $7.49 | +2.27% |
Click any year to see its month-by-month SGHT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, SGHT is projected to trade between $3.45 and $7.49, averaging $5.32 — a potential gain of 0% from today's $5.32. A consolidation phase looks the most probable path here.
Sight Sciences, Inc.'s 2027 outlook centres on $7.36, within a $5.85 to $9.81 range. That is up +38% on the projected 2026 average. That marks a +38% change versus current levels. Momentum favours further upside here.
By 2028, SGHT could reach as high as $10.74, with a base case around $7.76 and support toward $5.99 — roughly +46% from $5.32. Buyers look set to stay in control over this stretch.
Expect SGHT to range from $6.25 to $11.81 through 2029. The $8.29 average target implies a +56% move from current prices. That is up +7% on the projected 2028 average. Momentum favours further upside here.
The SGHT price prediction for 2030 points to an average of $8.78 (low $6.49, high $12.83) — a potential gain of +65% on today's $5.32. Buyers look set to stay in control over this stretch.
In 2031, SGHT is projected to trade between $6.75 and $13.90, averaging $9.31 — a potential gain of +75% from today's $5.32. That is up +6% on the projected 2030 average. Momentum favours further upside here.
Sight Sciences, Inc.'s 2032 outlook centres on $11.35, within a $8.08 to $17.27 range. That is up +22% on the projected 2031 average. That marks a +113% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, SGHT could reach as high as $19.98, with a base case around $12.90 and support toward $9.03 — roughly +142% from $5.32. Momentum favours further upside here.
Expect SGHT to range from $9.81 to $22.41 through 2034. The $14.24 average target implies a +168% move from current prices. That is up +10% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The SGHT price prediction for 2035 points to an average of $15.31 (low $10.39, high $24.47) — a potential gain of +188% on today's $5.32. Momentum favours further upside here.
In 2040, SGHT is projected to trade between $14.71 and $39.51, averaging $23.23 — a potential gain of +337% from today's $5.32. That is up +52% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Sight Sciences, Inc.'s 2050 outlook centres on $40.65, within a $22.85 to $75.75 range. That is up +75% on the projected 2040 average. That marks a +664% change versus current levels. Momentum favours further upside here.
Investing $1,000 in SGHT today (≈ 187.969925 SGHT) could be worth
$7,640.57
+$6,640.57 (+664%) by 2050 · US Dollar
Based on the average projected SGHT price of $40.65 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SGHTwould be worth at today's price.
$1,000 invested in SGHT on Jul 10, 2025 (≈ 291.545184 SGHT) would be worth
$1,551.02
+$551.02 (+55.1%) today · 1.55× · US Dollar
Based on a SGHT entry price of $3.43 vs. today's $5.32.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $5.45 | $976.15 | -2.4% |
| 1 month ago | $4.82 | $1,103.73 | +10.4% |
| 3 months ago | $3.45 | $1,542.03 | +54.2% |
| 6 months ago | $7.41 | $717.95 | -28.2% |
| 1 year ago | $3.43 | $1,551.02 | +55.1% |
| All time (5.0y) ago | $33.5 | $158.81 | -84.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SGHT forecast.
Our base-case forecast reaches $11.00 around 2032.
Implied market cap at $11.00: $598.51M
The multi-year forecast points to a sustained upside from 2027 onward, with a series of rising averages and rising ROI. The 2027 average is $7.41 with a 40.8% ROI, followed by 2028 at $7.87 with 49.6%, 2029 at $8.44 with 60.4%, and 2030 at $9.05 with 72% ROI. The trajectory continues through 2031 ($9.70, 84.5%), 2032 ($11.96, 127.4%), 2033 ($13.67, 159.9%), 2034 ($15.13, 187.7%), and 2035 ($16.28, 209.4%).
By 2040 the forecast shows an average price of $25.28 with a 380.6% ROI, and by 2050 an average of $45.21 with a 759.4% ROI. These figures imply meaningful upside potential but are estimates, not guarantees, and reflect variable market conditions and assumptions over the coming years.
Tap a question to reveal the answer.
The forecasted average price in 2030 is $9.05, with a min of $6.65 and a max of $13.29, and an expected ROI of 72%. The sentiment is bullish.
The forecast shows bullish sentiment from 2027 onward, with rising averages and ROI figures (e.g., 40.8% in 2027, 49.6% in 2028, 60.4% in 2029, 72% in 2030, and up to 759.4% by 2050). However, 2026 is neutral, and these are estimates, not guarantees.
No. The maximum forecasted average price by 2050 is $45.21 with a max of $85.13, which does not reach $100.
The 30-day range is $4.35 to $6.35.
Current price is $5.26 and market cap is $286.2M.
Sight Sciences, Inc. Community Discussion
0Share your Sight Sciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.